Recipharm completes refinancing, extends debt maturities by seven years

• Recipharm completed a refinancing that extends its debt maturity profile by seven years, supporting continued investment in specialist capabilities.
• Moody's Ratings assigned a B2 Corporate Family Rating with a stable outlook, improving its credit assessment.
• S&P Global Ratings assigned Recipharm Holding a long-term issuer credit rating of B with a stable outlook, an improvement.
• Fitch affirmed its Long-Term Issuer Default Rating of B with a stable outlook.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recipharm AB published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.